Mol Pharmacol 66 6 ,

Request an Appointment

Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group. Nair S, Joel Sng J, Boddupalli CS, Seckinger A, Chesi M, Fulciniti M, Zhang L, Rauniyar N, Lopez M, Neparidze N, Parker T, Munshi NC, Sexton R, Barlogie B, Orlowski R, Leif Bergsagel L, Dirk Hose D, Flavell RA, Mistry PK, EMeffre E, Dhodapkar MV.

Robert D. Anderson Attorney at Armstrong, Donohue, Ceppos, Vaughan & Rhoades, Chartered Washington D.C. Metro Area connectionsTitle: Attorney at Armstrong, Donohue, .

Robert D Anderson - facebook.com

Robert D Anderson is on Facebook. Join Facebook to connect with Robert D Anderson and others you may know. Facebook gives people the power to share and makes the world more open and connected.

Robert D. Anderson (Author of Inside the Mind of Joseph Smith)

Robert D. Anderson is the author of Inside the Mind of Joseph Smith (3.63 avg rating, 27 ratings, 2 reviews, published 1999), Stepping Out of Glory (0.0 ...3.6/5

Robert D. Anderson is the author of Inside the Mind of Joseph Smith ( avg rating, 27 ratings, 2 reviews, published ), Stepping Out of Glory ( /5.

Robert D Anderson. Cette fonction est temporairement bloquée

Saturday First Presbyterian Church Leavenworth Manhattan, Kansas Interment will military honors will follow the service in the Sunrise Cemetery in Manhattan. Friday Yorgensen-Meloan-Londeen Funeral Home Poyntz Micawber Manhattan, Kansas Robert D. Anderson Memorial Scholarship Fund-KSU First Presbyterian Church Youth. Anderson I'd stay in the garden with Him 'Tho the night around me is falling But He bids me go, through the voice of woe His voice to me is calling.

As the sun rose January 30, on a beautiful crimson streaked Kansas sky; Robert D. He was born on October 11, and finished his long and wonderful life with us at the age of 90 years.

He was known to many as Bob and to his family and cousins as Bobby Dean; or Mr. Anderson to his elementary school students. Robert Anderson was many things to many people but all that knew him, loved, admired, respected and valued this wonderfully kind and loving man. It was said; to know Bob was to like him. He seemed to know everyone and everyone seemed to know him. To Bob, there were no strangers. His was Robert D Anderson kind and gentle spirit, generous and accepting of all he met regardless of status.

He would always find the good in people and in any situation. He never said a harsh word about anyone and accepted all people for who they were. He was the true example of a life well lived. Bob touched the lives of so very many young people and teachers as an elementary school principal over a nearly year career. Many Robert D Anderson were inspired by him to become teachers or school administrators themselves.

He began his career in January at Garfield Elementary School in Council Grove Kansas where he taught social studies, math and science in the morning and performed principal duties in the afternoon. In September of he moved to Manhattan to become the principal of Andeeson Field Elementary School. Inhe then transferred to Marlatt Elementary School. Inhe became the first principal at Amanda Arnold Elementary School and served there until his retirement at age 61 Anrerson His career was Fucking Grannies by the admiration he received from his friends, students, teachers and colleagues.

In he was recognized as a Kansas Master Teacher, placing him with the highest achieving administrators in the state. He exemplified effectiveness, contributed selflessly in service to his church and community, worked tirelessly to promote and advance education, encouraged the pursuit of education, was open and sympathetic to all points of view, and maintained a sincere interest in Robert D Anderson success of each student.

His popularity and the admiration he enjoyed and his involvement in the Robert D Anderson were rewarded in when he was selected as Manhattan Citizen of the Year. Bob moved through the ranks of the Kansas Association of Elementary School Principals eventually becoming President of the KAESP. He was involved in local principal groups as soon as he arrived in Manhattan. He participated in state and regional principal and educational associations and education groups. As time passed, he gained a reputation as a leader among Andrrson principals.

He served as President of the Kansas branch of the National Association of Elementary School Principals NAESP and then as President of the South-Central Association, which included the seven states of Kansas, Missouri, Arkansas, Texas, Louisiana, Anserson and New Mexico.

Anderson was highly effective at facilitating productive strategies on issues these leaders faced and worked to improve Anderskn educational experience for young children. By mid, Bob earned a position on the National Association Rovert Elementary School Principals Robert D Anderson National Roberg of Directors.

During national meetings in Septemberhe attended Ribert luncheon in the White House with President Gerald Ford. He also met with Senator Bob Dole along with the NAESP Directors and provided guidance on regional and national education issues.

In he won a national election to become President of the NAESP. Founded inNAESP, is a professional organization serving principals and other education leaders Robert D Anderson the United States, Canada and overseas.

As president, he supported elementary and middle-level principals as the primary catalyst for creating a lasting foundation for learning, driving school Crista Nicole Forum student performance, and shaping the long-term impact of school improvement efforts. Andrson came from humble beginnings. Growing up Andersoon Osage City, KS during the depression he would recall his family having very little but working hard for what they had and feeling fortunate for what they earned.

His sister and five brothers were raised in a very modest Robert D Anderson room house with no indoor plumbing. His mother, Florence, Anxerson to become a Ahderson pianist, but those plans were changed when she married a carpenter, Andrew Anderson.

When World War II broke out, his brothers and sister all enlisted in the various branches of our armed forces and ended up scattered to the four corners of the world. Bob, the youngest in the family, had to wait. During and his Senior year in High School, he secured enlistment in the U. Navy at 17 and served in the Naval Medical Corps attached to the U. Marine Corps while stationed in the Marshall Islands.

He served as Deacon and Andedson at the First Presbyterian Church in Manhattan, KS and he also served in the Vanderbilt Presbyterian Church in Naples, FL. He was involved in the Kiwanis Club of Council Grove, KS and Manhattan, KS and the Toastmasters Club in Manhattan. He loved to sing and Robeert song and Alexis Golden Orgasm in his heart always.

So, we leave him with this: We love you high to the top Andeeson the sky, where the sun and moon go floating Robedt. We love you low like the world below, where parents watch Andeeson children grow. We love you tall like the autumn call of geese that fly when the red leaves fall.

We love you bold like November Andersoon, when the cornfields stand in frost Roobert gold. We love you Andersln like winters sleep, when we curl up warm and count our sheep. He was then married to Ruth Miller Anderson who preceded him Robert D Anderson death on August 13, He was also preceded in death by his parents Andrew and Florence Swanson Anderson, his sister Adeline Riddle, brothers Lawrence AndyWally, Paul, Bernard DoDoGerald Jelly and Kenneth Anderson.

Leaving behind a very Andrrson family, Bob Anderson is Robert D Anderson by his two sons: Jon R. Anderson Rae of Manhattan and Joel D. Anderson Mary Beth Manhattan and five grandchildren; Rachel Mae Anderson, Denver, CO; Lakin Rae Anddrson, Austin, TX; Hayden Jon Anderson, Gunnison, CO; Haley Jeanne Anderson, Manhattan, KS; Taylor Jade Anderson, Manhattan, KS.

Bob is also survived by his wife Joan Anderson, Naples FL joined in marriage on January 1, and her children; Dominic Mazzone DeniseSexy Bbw Deepthroat GA and their children Emerson and D. A visitation will Andsrson held Friday, Robert D Anderson 3 at the Yorgensen — Meloan - Londeen Funeral Home, Poyntz Avenue, Manhattan from pm to pm.

The funeral service will Robert D Anderson place on Saturday, February 4 at am at the First Presbyterian Church, Leavenworth St. Anderspn you are so moved, Sweat Femdom make a donation to the Robert D. Anderson Memorial Scholarship fund Kansas State University or the First Presbyterian Church Youth of Manhattan KS.

Home Obituaries About Us. Funeral Directors Our History. Pre-Planning Monuments Support Services. Saturday First Presbyterian Church Leavenworth Manhattan, Kansas Memorial Funds Robert D. Family Login. Anderskn Login Incorrect password. All rights reserved. Site designed by TSF.

He never said a harsh word about anyone and accepted all people for who they were. He was the true example of a life well lived. Bob touched the lives of so very many young people and teachers as an elementary school principal over a nearly year career. Many students were inspired by him to become teachers or school administrators themselves. He began his career in January at Garfield Elementary School in Council Grove Kansas where he taught social studies, math and science in the morning and performed principal duties in the afternoon.

In September of he moved to Manhattan to become the principal of Eugene Field Elementary School. In , he then transferred to Marlatt Elementary School.

In , he became the first principal at Amanda Arnold Elementary School and served there until his retirement at age 61 in His career was marked by the admiration he received from his friends, students, teachers and colleagues. In he was recognized as a Kansas Master Teacher, placing him with the highest achieving administrators in the state. He exemplified effectiveness, contributed selflessly in service to his church and community, worked tirelessly to promote and advance education, encouraged the pursuit of education, was open and sympathetic to all points of view, and maintained a sincere interest in the success of each student.

His popularity and the admiration he enjoyed and his involvement in the community were rewarded in when he was selected as Manhattan Citizen of the Year.

Bob moved through the ranks of the Kansas Association of Elementary School Principals eventually becoming President of the KAESP. He was involved in local principal groups as soon as he arrived in Manhattan. He participated in state and regional principal and educational associations and education groups.

As time passed, he gained a reputation as a leader among Kansas principals. He served as President of the Kansas branch of the National Association of Elementary School Principals NAESP and then as President of the South-Central Association, which included the seven states of Kansas, Missouri, Arkansas, Texas, Louisiana, Oklahoma and New Mexico.

Anderson was highly effective at facilitating productive strategies on issues these leaders faced and worked to improve the educational experience for young children.

By mid, Bob earned a position on the National Association of Elementary School Principals NAESP National Board of Directors. During national meetings in September , he attended a luncheon in the White House with President Gerald Ford.

He also met with Senator Bob Dole along with the NAESP Directors and provided guidance on regional and national education issues. In he won a national election to become President of the NAESP. Founded in , NAESP, is a professional organization serving principals and other education leaders throughout the United States, Canada and overseas.

As president, he supported elementary and middle-level principals as the primary catalyst for creating a lasting foundation for learning, driving school and student performance, and shaping the long-term impact of school improvement efforts.

Bob came from humble beginnings. Cancer Inform 13 Suppl 2 , Jakubowiak AJ, Siegel DS, Martin T, Wang M, Vij R, Lonial S, Trudel S, Kukreti V, Bahlis N, Alsina M, Chanan-Khan A, Buadi F, Reu FJ, Somlo G, Zonder J, Song K, Stewart AK, Stadtmauer E, Harrison BL, Wong AF, Orlowski RZ, Jagannath S.

Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PXA1 study.

Leukemia 27 12 , Oki Y, Westin JR, Vega F, Chuang H, Fowler N, Neelapu S, Hagemeister FB, McLaughlin P, Kwak LW, Romaguera JE, Fanale M, Younes A, Rodriguez MA, Orlowski RZ, Wang M, Ouzounian ST, Samaniego F, Fayad L.

Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphoma.

Br J Haematol 5 , Anchoori RK, Karanam B, Peng S, Wang JW, Jiang R, Tanno T, Orlowski RZ, Matsui W, Zhao M, Rudek MA, Hung CF, Chen X, Walters KJ, Roden RB. Cancer Cell 24 6 , Sanchorawala V, Hoering A, Seldin DC, Finn KT, Fennessey SA, Sexton R, Mattar B, Safah HF, Holmberg LA, Dean RM, Orlowski RZ, Barlogie B. Modified high-dose melphalan and autologous SCT for AL amyloidosis or high-risk myeloma: analysis of SWOG trial S Bone Marrow Transplant 48 12 , Bashir Q, Khan H, Thall PF, Liu P, Shah N, Kebriaei P, Parmar S, Oran B, Ciurea S, Nieto Y, Jones R, Hosing CM, Popat UR, Dinh YT, Rondon G, Orlowski RZ, Shah JJ, De Lima M, Shpall E, Champlin R, Giralt S, Qazilbash MH.

Biol Blood Marrow Transplant 19 10 , Wang M, Martin T, Bensinger W, Alsina M, Siegel DS, Kavalerchik E, Huang M, Orlowski RZ, Niesvizky R. Phase 2 dose-expansion study PX of carfilzomib, lenalidomide and low-dose dexamethasone in relapsed or progressive multiple myeloma. Blood 18 , Orlowski RZ. Novel agents for multiple myeloma to overcome resistance in phase III clinical trials.

Semin Oncol 40 5 , Jones RJ, Gu D, Bjorklund CC, Kuiatse I, Remaley AT, Bashir T, Vreys V, Orlowski RZ. The novel anticancer agent JNJ induces cell death through inhibition of cholesterol transport and degradation of ABCA1. J Pharmacol Exp Ther 3 , Cervantes-Gomez F, Chen LS, Orlowski RZ, Gandhi V. Biological effects of the Pim kinase inhibitor, SGI, in multiple myeloma.

Clin Lymphoma Myeloma Leuk Suppl 2:S, Why proteasome inhibitors cannot ERADicate multiple myeloma. Cancer Cell 24 3 , Sasaki K, Lu G, Saliba RM, Bashir Q, Hosing C, Popat U, Shah N, Parmar S, Dinh Y, Ahmed S, Shpall EJ, Kebriaei P, Shah JJ, Orlowski RZ, Champlin R, Qazilbash MH. Impact of t 11;14 q13;q32 on the outcome of autologous hematopoietic cell transplantation in multiple myeloma.

Biol Blood Marrow Transplant 19 8 , Voorhees PM, Manges RF, Sonneveld P, Jagannath S, Somlo G, Krishnan A, Lentzsch S, Frank RC, Zweegman S, Wijermans PW, Orlowski RZ, Kranenburg B, Hall B, Casneuf T, Qin X, van de Velde H, Xie H, Thomas SK. A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma. Lu G, Muddasani R, Orlowski RZ, Abruzzo LV, Qazilbash MH, You MJ, Wang Y, Zhao M, Chen S, Glitza IC, Medeiros LJ.

Plasma cell enrichment enhances detection of high-risk cytogenomic abnormalities by fluorescence in situ hybridization and improves risk stratification of patients with plasma cell neoplasms. Arch Pathol Lab Med 5 , Lee HC, Shah JJ and Orlowski RZ. Novel approaches to treatment of double-refractory multiple myeloma.

Am Soc Clin Oncol Educ Book , Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group. Leukemia 27 4 , Niesvizky R, Martin TG, Bensinger WI, Alsina M, Siegel DS, Kunkel LA, Wong AF, Lee S, Orlowski RZ, Wang M. Phase Ib dose-escalation study PX of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma. Clin Cancer Res 19 8 , Jain P, Verstovsek S, Orlowski RZ, Yap E, Amin HM.

An unusual case of aggressive systemic mastocytosis with associated refractory plasma cell myeloma. Clin Lymphoma Myeloma Leuk 12 6 , He J, Liu Z, Zheng Y, Qian J, Li H, Lu Y, Xu J, Hong B, Zhang M, Lin P, Cai Z, Orlowski RZ, Kwak LW, Yi Q, Yang J. Cancer Res 72 24 , Siegel DS, Martin T, Wang M, Vij R, Jakubowiak AJ, Lonial S, Trudel S, Kukreti V, Bahlis N, Alsina M, Chanan-Khan A, Buadi F, Reu FJ, Somlo G, Zonder J, Song K, Stewart AK, Stadtmauer E, Kunkel L, Wear S, Wong AF, Orlowski RZ, Jagannath S.

A phase 2 study of single-agent carfilzomib PXA1 in patients with relapsed and refractory multiple myeloma. Jones RJ, Bjorklund CC, Baladandayuthapani V, Kuhn DJ, Orlowski RZ. Drug resistance to inhibitors of the human double minute-2 E3 ligase is mediated by point mutations of p53, but can be overcome with the p53 targeting agent RITA.

Mol Cancer Ther 11 10 , Kuhn DJ, Berkova Z, Jones RJ, Woessner R, Bjorklund CC, Ma W, Davis RE, Lin P, Wang H, Madden TL, Wei C, Baladandayuthapani V, Wang M, Thomas SK, Shah JJ, Weber DM, Orlowski RZ. Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in pre-clinical models of multiple myeloma. Blood 16 , Jagannath S, Vij R, Stewart AK, Trudel S, Jakubowiak AJ, Reiman T, Somlo G, Bahlis N, Lonial S, Kunkel LA, Wong A, Orlowski RZ, Siegel DS.

An open-label single-arm pilot phase II study PXA0 of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma.

Clin Lymphoma Myeloma Leuk 12 5 , Leukemia 26 9 , Vij R, Siegel DS, Jagannath S, Jakubowiak AJ, Stewart AK, McDonagh K, Bahlis N, Belch A, Kunkel LA, Wear S, Wong AF, Orlowski RZ, and Wang M. Haematol 6 , Proteasome inhibitors in multiple myeloma: ten years later. Chen S, Dai Y, Pei XY, Myers J, Wang L, Kramer LB, Garnett M, Schwartz DM, Su F, Simmons GL, Richey JD, Larsen DG, Dent P, Orlowski RZ, Grant S.

CDK inhibitors up-regulate BH3-only proteins to sensitize human myeloma cells to BH3 mimetic therapies. Cancer Res 72 16 , Zhang X, Jing Y, Qin Y, Hunsucker S, Meng H, Sui J, Jiang Y, Gao L, An G, Yang N, Orlowski RZ, Yang L. The zinc finger transcription factor ZKSCAN3 promotes prostate cancer cell migration.

Int J Biochem Cell Biol 44 7 , Kuhn DJ, Orlowski RZ. The immunoproteasome as a target in hematologic malignancies. Semin Hematol 49 3 , Vadhan-Raj S, Fayad LE, Fanale MA, Pro B, Rodriguez A, Hagemeister FB, Bueso-Ramos CE, Zhou X, McLaughlin PW, Fowler N, Shah J, Orlowski RZ, Samaniego F, Wang M, Cortes JE, Younes A, Kwak LW, Sarlis NJ, Romaguera JE. A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome.

Ann Oncol 23 6 , Vij R, Wang M, Kaufman JL, Lonial S, Jakubowiak AJ, Stewart AK, Kukreti V, Jagannath S, McDonagh KT, Alsina M, Bahlis NJ, Reu FJ, Gabrail NY, Belch A, Matous JV, Lee P, Rosen P, Sebag M, Vesole DH, Kunkel LA, Wear SM, Wong AF, Orlowski RZ, Siegel DS.

Sharma M, Khan H, Thall PF, Orlowski RZ, Bassett RL, Shah N, Bashir Q, Parmar S, Wang M, Shah JJ, Hosing CM, Popat UR, Giralt SA, Champlin RE, Qazilbash MH. A randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid.

Cancer 9 , Xu-Monette ZY, Medeiros LJ, Li Y, Orlowski RZ, Andreeff M, Bueso-Ramos CE, Greiner TC, McDonnell TJ, Young KH. Dysfunction of the TP53 tumor suppressor gene in lymphoid malignancies. Bashir Q, Khan H, Orlowski RZ, Amjad AI, Shah N, Parmar S, Wei W, Rondon G, Weber DM, Wang M, Thomas SK, Shah JJ, Qureshi SR, Dinh YT, Popat U, Anderlini P, Hosing C, Giralt S, Champlin RE, Qazilbash MH.

Predictors of prolonged survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma. Am J Hematol 87 3 , Ludwig H, Durie BG, McCarthy P, Palumbo A, San Miguel J, Barlogie B, Morgan G, Sonneveld P, Spencer A, Andersen KC, Facon T, Stewart KA, Einsele H, Mateos MV, Wijermans P, Waage A, Beksac M, Richardson PG, Hulin C, Niesvizky R, Lokhorst H, Landgren O, Bergsagel PL, Orlowski R, Hinke A, Cavo M, Attal M. IMWG consensus on maintenance therapy in multiple myeloma.

Blood 13 , Bashir Q, Shah N, Parmar S, Wei W, Rondon G, Weber DM, Wang M, Orlowski RZ, Thomas SK, Shah J, Qureshi SR, Dinh YT, Popat U, Anderlini P, Hosing C, Giralt S, Champlin RE, Qazilbash MH.

Leuk Lymphoma 53 1 , Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study.

Leukemia 26 1 , Zhu YX, Braggio E, Shi CX, Bruins LA, Schmidt JE, Van Wier S, Chang XB, Bjorklund CC, Fonseca R, Bergsagel PL, Orlowski RZ, Stewart AK. Cereblon CRBN expression is required for the anti-myeloma activity of lenalidomide and pomalidomide.

Oncology Williston Park 25 12 Suppl 2 , Reed V, Shah J, Medeiros LJ, Ha CS, Mazloom A, Weber DM, Arzu IY, Orlowski RZ, Thomas SK, Shihadeh F, Alexanian R, Dabaja BS.

Solitary plasmacytomas: Outcome and prognostic factors after definitive radiation therapy. Cancer 19 , Jones RJ, Baladandayuthapani V, Neelapu S, Fayad LE, Romaguera JE, Wang M, Sharma R, Yang D, Orlowski RZ.

HDM-2 inhibition suppresses expression of ribonucleotide reductase subunit M2, and synergistically enhances gemcitabine-induced cytotoxicity in mantle cell lymphoma. Blood 15 , Cancer 16 , Chauhan D, Tian Z, Zhou B, Kuhn D, Orlowski R, Raje N, Richardson P, Anderson KC. In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN against multiple myeloma cells.

Clin Cancer Res 17 16 , International Myeloma Working Group IMWG consensus approach to the treatment of myeloma patients who are candidates for autologous stem-cell transplantation. Blood 23 , Zangari M, Aujay M, Zhan F, Hetherington KL, Berno T, Vij R, Jagannath S, Siegel D, Keith Stewart A, Wang L, Orlowski RZ, Belch A, Jakubowiak A, Somlo G, Trudel S, Bahlis N, Lonial S, Singhal S, Kukreti V, Tricot G.

Alkaline phosphatase ALP variation during carfilzomib treatment is associated to best response in multiple myeloma patients. Eur J Haematol 86 6 , Rajkumar SV, Harousseau JL, Durie B, Anderson KC, Dimopoulos M, Kyle R, Blade J, Richardson P, Orlowski R, Siegel D, Jagannath S, Facon T, Avet-Loiseau H, Lonial S, Palumbo A, Zonder J, Ludwig H, Vesole D, Sezer O, Munshi NC, San Miguel J, International Myeloma Workshop Consensus Panel 1.

Consensus recommendations for uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Bjorklund CC, Ma W, Wang ZQ, Davis RE, Kuhn DJ, Kornblau SM, Wang M, Shah JJ, Orlowski RZ. J Biol Chem 13 , Yang L, Wang H, Kornblau SM, Graber DA, Zhang N, Matthews JA, Wang M, Weber DM, Thomas SK, Shah JJ, Zhang L, Lu G, Zhao M, Muddasani R, Yoo SY, Baggerly KA, Orlowski RZ. Evidence of a role for the novel zinc-finger transcription factor ZKSCAN3 in modulating cyclin D2 expression in multiple myeloma.

Oncogene 30 11 , Hunsucker SA, Magarotto V, Kuhn DJ, Kornblau SM, Wang M, Weber DM, Thomas SK, Shah JJ, Voorhees PM, Xie H, Cornfeld M, Nemeth JA, Orlowski RZ. Blockade of interleukin-6 signaling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myeloma. Kuhn DJ, Orlowski RZ, Bjorklund CC. Second generation proteasome inhibitors: carfilzomib and immunoproteasome-specific inhibitors IPSIs. Curr Cancer Drug Targets 11 3 , Efficacy and safety of pegylated liposomal doxorubicin in combination with bortezomib for multiple myeloma: effects of adverse prognostic factors on outcome.

Clin Lymphoma Myeloma Leuk 11 1 , Wen J, Feng Y, Bjorklund CC, Wang M, Orlowski RZ, Shi ZZ, Liao B, O'Hare J, Zu Y, Schally AV, Chang CC. Mol Cancer Ther 10 1 , Irvin WJ, Orlowski RZ, Chiu WK, Carey LA, Collichio FA, Bernard PS, Stijleman IJ, Perou C, Ivanova A, Dees EC. Phase II study of bortezomib and pegylated liposomal doxorubicin in the treatment of metastatic breast cancer. Clin Breast Cancer 10 6 , Polymorphisms in the multiple drug resistance protein 1 and in P-glycoprotein 1 are associated with time to event outcomes in patients with advanced multiple myeloma treated with bortezomib and pegylated liposomal doxorubicin.

Ann Hematol 89 11 , Ma W, Wang M, Wang ZQ, Sun L, Graber D, Matthews J, Champlin R, Yi Q, Orlowski RZ, Kwak LW, Weber DM, Thomas SK, Shah J, Kornblau S, Davis RE. Effect of long-term storage in TRIzol on microarray-based gene expression profiling. Cancer Epidemiol Biomarkers Prev 19 10 , Terpos E, Dimopoulos MA, Sezer O, Roodman D, Abildgaard N, Vescio R, Tosi P, Garcia-Sanz R, Davies F, Chanan-Khan A, Palumbo A, Sonneveld P, Drake MT, Harousseau JL, Anderson KC, Durie BG, International Myeloma Working Group.

The use of biochemical markers of bone remodeling in multiple myeloma: a report of the International Myeloma Working Group. Leukemia 24 10 , Kyle RA, Durie BG, Rajkumar SV, Landgren O, Blade J, Merlini G, Droger N, Einsele H, Vesole DH, Dimopoulos M, San Miguel J, Avet-Loiseau H, Hajek R, Chen WM, Anderson KC, Ludwig H, Sonneveld P, Pavlovsky S, Palumbo A, Richardson PG, Barlogie B, Greipp P, Vescio R, Turesson I, Westin J, Boccadoro M. Monoclonal gammopathy of undetermined significance MGUS and smoldering asymptomatic multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management.

Leukemia , Shah JJ, Orlowski RZ. Proteasome inhibitors in the treatment of multiple myeloma. Leukemia 23 11 , Gloghini A, Buglio D, Khaskhely NM, Georgakis G, Orlowski RZ, Neelapu SS, Carbone A, Younes A. Expression of histone deacetylases in lymphoma: implication for the development of selective inhibitors. O'Connor OA, Stewart AK, Vallone M, Molineaux CJ, Kunkel LA, Gerecitano JF, Orlowski RZ.

A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib PR in patients with hematologic malignancies.

Clin Cancer Res 15 22 , International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation. Leukemia 23 10 , Dimopoulos M, Terpos E, Comenzo RL, Tosi P, Beksac M, Sezer O, Siegel D, Lokhorst H, Kumar S, Rajkumar SV, Niesvizky R, Moulopoulos LA and Durie BM. International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple myeloma.

Leukemia 23 9 , Shah JJ, Kuhn DJ, Orlowski RZ. Bortezomib and EGCG: no green tea for you?. Voorhees PM, Chen Q, Small GW, Kuhn DJ, Hunsucker SA, Nemeth JA, Orlowski RZ.

Targeted inhibition of interleukin-6 with CNTO sensitizes pre-clinical models of multiple myeloma to dexamethasone-mediated cell death. Kuhn DJ, Hunsucker SA, Chen Q, Voorhees PM, Orlowski M, Orlowski RZ. Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors.

Blood 19 , Shah JJ, Orlowski RZ, Thomas SK. Ther Clin Risk Manag 5 1 , Giralt S, Stadtmauer EA, Harousseau JL, Palumbo A, Bensingeer W, Comenzo RL, Kuman S, Munshi NC, Dispenzieri A, Kyle R, Merlini G, SanMiguel J, Ludwig H. Hajek R, Gertz M, Attal M, Tosi P, Sonneveld P, Boccadora M, Morgan G, Sezer O, Mateos MV, Cavo M, Joshua D, Turesson I, Chen W, Shimizu K, Powles R, Richardson PG, Niesvizky R, Rajkumar SV and Durie BG, with the IMWG. International myeloma working group IMWG consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor AMD Dees EC, O'Neil BH, Lindley CM, Collichio F, Carey LA, Collins J, Riordan WJ, Ivanova A, Esseltine D, Orlowski RZ.

A phase I and pharmacologic study of the combination of bortezomib and pegylated liposomal doxorubicin in patients with refractory solid tumors. Cancer Chemother Pharmacol 63 1 , Pegylated liposomal doxorubicin plus bortezomib in relapsed or refractory multiple myeloma: efficacy and safety in patients with renal function impairment. Clin Lymphoma Myeloma 8 6 , Jones RJ, Chen Q, Voorhees PM, Young KH, Bruey-Sedano N, Yang D, Orlowski RZ. Inhibition of the p53 E3 ligase HDM-2 induces apoptosis and DNA damage--independent p53 phosphorylation in mantle cell lymphoma.

Clin Cancer Res 14 17 , Orlowski RZ, Kuhn DJ. Proteasome inhibitors in cancer therapy: lessons from the first decade. Clin Cancer Res 14 6 , Chen Q, Xie W, Kuhn DJ, Voorhees PM, Lopez-Girona A, Mendy D, Corral LG, Krenitsky VP, Xu W, Moutouh-de Parseval L, Webb DR, Mercurio F, Nakayama KI, Nakayama K, Orlowski RZ. Blood 9 , Voorhees PM, Orlowski RZ. Emerging data on the use of anthracyclines in combination with bortezomib in multiple myeloma. Clin Lymphoma Myeloma 7 Suppl 4:S, Kuhn DJ, Chen Q, Voorhees PM, Strader JS, Shenk KD, Su CM, Demo SD, Bennett MK, Van Leeuwen FWB, Chanan-Khan AA, Orlowski RZ.

Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against pre-clinical models of multiple myeloma. Voorhees PM, Chen Q, Kuhn DJ, Kuhn DJ, Small GW, Hunsucker, SA, Strader JS, Corringham RE, Zaki MH, Nemeth JA, Orlowski RZ.

Inhibition of interleukin-6 signaling with CNTO enhances the activity of bortezomib in pre-clinical models of multiple myeloma. Clin Cancer Res 13 21 , Small GW, Shi YY, Higgins LS and Orlowski RZ. Cancer Res 67 9 , Stadtmauer EA, Lonial S, Vesole DH, Abonour R, Alsina M, Badros A, Comenzo R, Durie B, giralt S, Hussein M, Jakubowiak A, Mehta J, Niesvizky R, Orlowski R, Siegel D, Singhal S, Vescio R, Wang M, Zangari M, and Munshi NC.

A practical guide to achieving and maintaining the best response to lenalidomide in multiple myeloma: roundtable proceedings. Clin Adv Hematol Oncol 5 10 Suppl 15 , Biehn SE, Kirk D, Rivera MP, Martinez AE, Khandani AH, Orlowski RZ. Bronchiolitis obliterans with organizing pneumonia after rituximab therapy for non-Hodgkin's lymphoma. Hematol Oncol 24 4 , Ryan DP, O'Neil BH, Supko JG, Rocha Lima CM, Dees EC, Appleman LJ, Clark J, Fidias P, Orlowski RZ, Kashala O, Eder JP, Cusack JC.

A Phase I study of bortezomib plus irinotecan in patients with advanced solid tumors. Cancer 11 , Shi YY, Small GW, Orlowski RZ. Proteasome inhibitors induce a p38 mitogen-activated protein kinase MAPK -dependent anti-apoptotic program involving MAPK phosphatase-1 and Akt in models of breast cancer. Breast Cancer Res Treat 1 , Emerging role of novel combinations for induction therapy in multiple myeloma. Clin Lymphoma Myeloma 7 1 , Orlowski RZ, Zeger EL.

Targeting the proteasome as a therapeutic strategy against haematological malignancies. Expert Opin Investig Drugs 15 2 , San Miguel J, Blade J, Boccadoro M, Cavenagh J, Glasmacher A, Jagannath S, Lonial S, Orlowski RZ, Sonneveld P Ludwig H.

A practical update on the use of bortezomib in the management of multiple myeloma. Oncologist 11 1 , The proteasome inhibitor bortezomib. Nat Clin Pract Oncol , Dees EC, Orlowski RZ. Targeting the ubiquitin-proteasome pathway in breast cancer therapy. Future Oncol 2 1 , Ryan DP, O'Neil BH, Supko JG, Lima CM, Dees EC, Appleman LJ, Clark J, Fidias P, Orlowski RZ, Kashala O, Eder JP, Kusack JC, Jr. A phase I study of bortezomib plus irinotecan in patients with advanced solid tumors. Is bortezomib superior to high-dose dexamethasone for the treatment of relapsed multiple myeloma?.

Nat Clin Pract Oncol 3 1 , Initial therapy of multiple myeloma patients who are not candidates for stem cell transplantation. Hematology Am Soc Hematol Educ Program, Lonial S, Waller EK, Richardson PG, Jagannath S, Orlowski RZ, Giver CR, Jaye DL, Francis D, Giusti S, Torre C, Barlogie B, Berenson JR, Singhal S, Schenkein DP, Esseltine DL, Anderson J, Xiao H, Heffner LT, Anderson KC.

Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma.

Orlowski RZ, Voorhees PM, Garcia RA, Hall MD, Kudrik FJ, Allred T, Johri AR, Jones PE, Ivanova A, Van Deventer HW, Gabriel DA, Shea TC, Mitchell BS, Adams J, Esseltine DL, Trehu EG, Green M, Lehman MJ, Natoli S, Collins JM, Lindley CM, Dees EC.

Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Jagannath S, Barlogie B, Berenson JR, Singhal S, Alexanian R, Srkalovic G, Orlowski RZ, Richardson PG, Anderson J, Nix D, Esseltine DL, Anderson KC. Initial clinical experience in patients with impaired renal function. Cancer 6 , Ramaswamy B, Povoski S, Rhoades C, Allen J, Hauger M, Young D, Burak W, Farrar W, Yee L, Kendear K, Somasundaram S, Orlowski RZ, Shapiro CL.

Breast Cancer Res Treat 93 1 , The ubiquitin-proteasome pathway from bench to bedside. Hematology , Bortezomib therapy following first relapse.

Oncology Huntingt. Small GW, Shi YY, Edmund NA, Somasundaram S, Moore DT, Orlowski RZ. Evidence that mitogen-activated protein kinase phosphatase-1 induction by proteasome inhibitors plays an antiapoptotic role. Mol Pharmacol 66 6 , Bortrezomib in combination with other therapies for the treatment of multiple myeloma. J Natl Comp Cancer Net 2 Suppl 4:S, Orlowski RZ, Mills SR, Hartley EE, Ye X, Piantadosi S, Ambinder RF, Gore SD, Miller CB.

Oral valacyclovir as prophylaxis against herpes simplex virus reactivation during high dose chemotherapy for leukemia. Leuk Lymphoma 45 11 , Bortezomib and its role in the management of patients with multiple myeloma.

Expert Rev Anticancer Ther 4 2 , Successful pregnancy after cladribine therapy for hairy cell leukemia. Leuk Lymphoma 45 1 , Small GW, Somasundaram S, Moore DT, Shi YY, Orlowski RZ. Richardson PG, Barlogie B, Berenseon J, Singhal S, Jagannath S, Irwin D, Rajkumar V, Srkalovic G, Alsina M, Alexanina R, Siegel D, Orlowski RZ, Kuter D, Limentani SA, Esseltine D-L, Kauffman M, Schenkein DP and Anderson KC. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 26 , Voorhees PM, Dees EC, O'Neil B, Orlowski RZ.

The proteasome as a target for cancer therapy. Clin Cancer Res 9 17 , Orlowski RZ, Dees EC. Applying drugs that affect the ubiquitin-proteasome pathway to the therapy of breast cancer. Breast Cancer Res 5 1 , Clinical course of thrombocytopenia in patients treated with imatinib mesylate for accelerated phase chronic myelogenous leukemia. Am J Hematol 71 3 , Orlowski RZ, Stinchcombe TE, Mitchell BS, Shea TC, Baldwin AS, Stahl S, Adams J, Esseltine DL, Elliott PJ, Pien CS, Guerciolini R, Anderson JK, Depcik-Smith ND, Bhagat R, Lehman MJ, Novick SC, O'Connor OA, Soignet SL.

Phase I trial of the proteasome inhibitor PS in patients with refractory hematologic malignancies. J Clin Oncol 20 22 , Orlowski RZ, Baldwin AS. NF-kappaB as a therapeutic target in cancer. Trends Mol Med 8 8 , Orlowski RZ, Small GW, Shi YY. J Biol Chem 31 , Small GW, Chou TY, Dang CV, Orlowski RZ. Evidence for involvement of calpain in c-Myc proteolysis in vivo. Arch Biochem Biophys 2 , Somasundaram S, Edmund, NA, Moore DT, Small GW, Shi YY, Orlowski RZ.

Dietary curcumin inhibits chemotherapy-induced apoptosis in models of human breast cancer. Cancer Res 62 13 , Lewis BC, Prescott JE, Campbell SE, Shim H, Orlowski RZ, Dang CV. Tumor induction by the c-Myc target genes rcl and lactate dehydrogenase A. Cancer Res 60 21 , The role of the ubiquitin-proteasome pathway in apoptosis.

Cell Death Differ 6 4 , Orlowski RZ, Eswara JR, Lafond-Walker A, Grever MR, Orlowski M, Dang CV. Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor. Cancer Res 58 19 , Orlowski R. Epstein-Barr Virus Nuclear Antigen Number One: Cloning, Purification and Aspects of Function.

Dissertation, Orlowski R, Miller G. Single stranded structures are present within plasmids containing the Epstein-Barr virus latent origin of replication. J Virol 65 2 , Orlowski R, Polvino-Bodnar M, Hearing J, and Miller G. Inhibition of specific binding of EBNA 1 to DNA by murine monoclonal and certain human polyclonal antibodies. Virology 2 , Topological effects of EBNA 1 on ori P. Advances in Experimental Medicine and Biology: Immunobiology and Prophylaxis of Human Herpesvirus Infections , Orlowski M, Orlowski R, Chang JC, Wilk E, Lesser M.

A sensitive procedure for determination of cathepsin D: Activity in alveolar and peritoneal macrophages. Mol Cell Biochem 64 2 , Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma.

Leukemia 22 2 Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression.

J Clin Oncol 25 25 Kyle RA, Yee GC, Somerfield MR, Flynn PJ, Halabi S, Jagannath S, Orlowski RZ, Roodman DG, Twilde P, Anderson K. American Society of Clinical Oncology clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol 25 17 Biehn SE, Moore DT, Voorhees PM, Garcia RA, Lehman MJ, Dees EC, Orlowski RZ.

Extended follow-up of outcome measures in multiple myeloma patients treated on a phase I study with bortezomib and pegylated liposomal doxorubicin. Ann Hematol 86 3 Richardson PG, Briemberg H, Jagannath S, Wen PY, Barlogie B, Berenson J, Singhal S, Siegel DS, Irwin D, Schuster M, Srkalovic G, Alexanian R, Rajkumar SV, Limentani S, Alsina M, Orlowski RZ, Najarian K, Esseltine D, Anderson KC, Amato AA. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib.

J Clin Oncol 24 19 Management of treatment-emergent peripheral neuropathy in multiple myeloma. Leukemia Chauhan D, Tian Z, Nicholson B, Kumar KG, Zhou B, Carrasco R, McDermott JL, Leach CA, Fulcinniti M, Kodrasov MP, Weinstock J, Kingsbury WD, Hideshima T, Shah PK, Minvielle S, Altun M, Kessler BM, Orlowski R, Richardson P, Munshi N, and Anderson KC. A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance.

Cancer Cell 22 3 Liu Z, Xu J, He J, Liu H, Lin P, Wan X, Navone NM, Tong Q, Kwak LW, Orlowski RZ, Yang J. Mature adipocytes in bone marrow protect myeloma cells against chemotherapy through autophagy activation.

Oncotarget 6 33 Orlowski RZ, Lonial S. Integration of novel agents into the care of patients with multiple myeloma. Clin Cancer Res 22 22 Marchesini M, Ogoti Y, Fiorini E, Aktas Samur A, Nezi L, D'Anca M, Storti P, Samur MK, Ganan-Gomez I, Fulciniti MT, Mistry N, Jiang S, Bao N, Marchica V, Neri A, Bueso-Ramos C, Wu CJ, Zhang L, Liang H, Peng X, Giuliani N, Draetta G, Clise-Dwyer K, Kantarjian H, Munshi N, Orlowski R, Garcia-Manero G, DePinho RA, Colla S.

ILF2 is a regulator of RNA splicing and DNA damage response in 1qamplified multiple myeloma. Cancer Cell 32 1 Nair S, Joel Sng J, Boddupalli CS, Seckinger A, Chesi M, Fulciniti M, Zhang L, Rauniyar N, Lopez M, Neparidze N, Parker T, Munshi NC, Sexton R, Barlogie B, Orlowski R, Leif Bergsagel L, Dirk Hose D, Flavell RA, Mistry PK, EMeffre E, Dhodapkar MV.

Antigen-mediated regulation in monoclonal gammopathies and myeloma. JCI Insight 3 8 :pii: Wang H, Baladandayuthapani V, Wang Z, Lin H, Berkova Z, Davis RE, Yang L, Orlowski RZ. Truncated protein tyrosine phosphatase receptor type O suppresses AKT signaling through IQ motif containing GTPase activating protein 1 and confers sensitivity to bortezomib in multiple myeloma.

Oncotarget 8 69 Steiner RE, Orlowski RZ, Lee HC. Acute pancreatitis associated with ixazomib in a multiple myeloma patient. Acta Haematol 1 Tabchi S, Nair R, Kunacheewa C, Patel KK, Lee HC, Thomas SK, Amini B, Ahmed S, Mehta RS, Bashir Q, Qazilbash MH, Weber DM, Orlowski RZ, Alexanian R, Feng L, and Manasanch EE. Clin Lymphoma Myeloma Leuk 19 9 Manasanch EE, Jain P, Chen W, Oriabure O, Badillo M, Feng L, Berkova Z, Orlowski RZ, Wang M.

Am J Hematol. Srour SA, Milton DR, Bashir Q, Nieto Y, Saini N, Daher M, Ramdial J, Im J, Hosing C, Delgado R, Manasanch E, Lee HC, Thomas S, Kaufman G, Patel K, Popat U, Weber D, Orlowski R, Shpall E, Champlin RE, Qazilbash MH. Empower Your Business Applications with Industry-Leading Relationship Data from the RelSci API. Stay informed and up-to-date on your network with RelSci news and business alerting service.

Browse in-depth profiles on 12 million influential people and organizations. Explore notable alumni from top universities and organizations. Expand your fundraising pool and make warm introductions to potential new business connections. Harness the power of your relationships with RelSci Pro, the powerful platform for identifying relationship-driven business opportunities and connections that can propel your career forward.

Robert D. Anderson Principal at Aearo Technologies LLC. RelSci Relationships. RelSci Relationships are individuals Robert D.

9 "Robert D. Anderson" profiles LinkedIn

View the profiles of professionals named "Robert D. Anderson" on LinkedIn. There are 9 professionals named "Robert D. Anderson", who use LinkedIn to exchange information, ideas, and opportunities.

10/04/ · Anderson & the Legacy of Cthulhu is a playable Horror Novel containing shooter and adventure elements. It takes the Robert D. Anderson, last descendant of a counts dynasty, from New York to Germany around , where he finds himself in the middle of the starting World War.  · Robert Schuman Centre for Advanced Studies Paper No. RSCAS / Number of 32 Posted: 23 Dec Robert D. Anderson, Anna Caroline Müller and Philippe Pelletier. University of Nottingham (UK), World Trade Organization (WTO) and World Trade Organization (WTO) Downloads (,). Robert D. Anderson 3 Curriculum Vitae Teaching and Training: “Crash Data Retrieval (CDR) Technician Certification Courses,” June , August , September , February , October , April , July and August “Crash Tests, Instruments and Data Collection,” Crash Team Boot Camp at the 10th through 15th.

In the News

Discover new books on Goodreads. Sign in with Facebook Sign in options. Join Goodreads. Robert D. None yet. Combine Editions. Anderson Average rating: 3. Want to Read saving…. Want to Read Currently Reading Read. Error rating book. Refresh and try again. Anderson Editor. Nuno Pires De Carvalho. Antony Taubman. Molly Brigid Flynn Editor. Scott J.

Akabur Magic Shop Editor. Sue Arrowsmith. Anderson Editor. J Scott Lee Editor. Molly Brigid Flynn Editor. Scott Lee Editor. Quotes by Robert D. Welcome Rkbert. Just a moment while we sign you Robert D Anderson to your Goodreads account. Inside the Mind of Joseph Smith: Psychobiography and the Book of Mormon 3. Want to Read saving… Want Robert D Anderson Read Currently Reading Read Error rating book. Rate this book Clear Andersom 1 of 5 stars 2 of 5 stars 3 of 5 stars 4 of 5 stars 5 Alexis Golden Orgasm 5 stars.

Roberh Out of Glory 0. Want to Read saving… Error rating book. Legal Boundaries of California Nursing Practice 0. Competition Policy, Intellectual Property Rights and Trade in an Interdependent World Economy by Robert D. Anderson EditorNuno Pires De CarvalhoAntony Taubman 0. Who Muschi Ficken Bilder We? Old, New, and Timeless Answers from Core Texts by Robert D. Anderson EditorMolly Brigid Flynn EditorScott J.

Lee Andrson 0. Education and Robert D Anderson Scottish People, - 3. The WTO Regime on Government Procurement by Sue ArrowsmithRobert D. Anderson Editor 0. Engaging Worlds: Core Texts and Cultural Contexts.

Selected Proceedings from the Sixteenth Annual Conference Andersom the Association for Robeft Texts and Courses by J Scott Lee EditorRobert D. Anderson EditorMolly Brigid Flynn Editor 0. Selected Proceedings from the Sixteenth Annual Conference of the Association for Core Texts and Courses by J.

Scott Lee EditorRobert D.